GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verseon Corp (LSE:VERS) » Definitions » Return-on-Tangible-Equity

Verseon (LSE:VERS) Return-on-Tangible-Equity : -127.68% (As of Jun. 2019)


View and export this data going back to 2015. Start your Free Trial

What is Verseon Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Verseon's annualized net income for the quarter that ended in Jun. 2019 was £-19.87 Mil. Verseon's average shareholder tangible equity for the quarter that ended in Jun. 2019 was £15.56 Mil. Therefore, Verseon's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2019 was -127.68%.

The historical rank and industry rank for Verseon's Return-on-Tangible-Equity or its related term are showing as below:

LSE:VERS's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -46.43
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Verseon Return-on-Tangible-Equity Historical Data

The historical data trend for Verseon's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verseon Return-on-Tangible-Equity Chart

Verseon Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Return-on-Tangible-Equity
Get a 7-Day Free Trial - -22.74 -30.43 -38.02 -71.66

Verseon Semi-Annual Data
Dec11 Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.69 -47.93 -55.62 -89.00 -127.68

Competitive Comparison of Verseon's Return-on-Tangible-Equity

For the Biotechnology subindustry, Verseon's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verseon's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verseon's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Verseon's Return-on-Tangible-Equity falls into.



Verseon Return-on-Tangible-Equity Calculation

Verseon's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2018 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2018 )  (A: Dec. 2017 )(A: Dec. 2018 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2018 )  (A: Dec. 2017 )(A: Dec. 2018 )
=-17.029/( (30.955+16.57 )/ 2 )
=-17.029/23.7625
=-71.66 %

Verseon's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2019 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2019 )  (Q: Dec. 2018 )(Q: Jun. 2019 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2019 )  (Q: Dec. 2018 )(Q: Jun. 2019 )
=-19.872/( (16.57+14.559)/ 2 )
=-19.872/15.5645
=-127.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2019) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Verseon  (LSE:VERS) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Verseon Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Verseon's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Verseon (LSE:VERS) Business Description

Industry
Traded in Other Exchanges
N/A
Address
47071 Bayside Parkway, Fremont, CA, USA, 94538
Verseon Corp is a part of the healthcare sector in the United States. It is a technology-based pharmaceutical company with a computer-driven drug discovery platform. The company designs novel drug candidates that are unlikely to be found using conventional methods. It is also engaged in drug discovery programs such as the diabetic macular edema product candidates, which treat the diseases by controlled disruption of the kallikrein kinin cascade.

Verseon (LSE:VERS) Headlines